Valuation Metrics and Recent Changes
As of 26 May 2026, NGL Fine Chem’s price-to-earnings (P/E) ratio stands at 36.97, a figure that, while still elevated, marks a moderation from previous levels that classified the stock as very expensive. The price-to-book value (P/BV) ratio is currently 5.40, indicating a premium valuation but one that aligns more closely with sector norms. The enterprise value to EBITDA (EV/EBITDA) ratio is 25.61, reflecting strong operational earnings relative to enterprise value, albeit higher than many peers.
These valuation adjustments have coincided with a significant price appreciation, with the stock closing at ₹2,864.80, up 3.42% on the day and touching a high of ₹3,000.00, near its 52-week peak. This price action follows a remarkable year-to-date return of 103.32%, vastly outperforming the Sensex, which has declined by 10.25% over the same period.
Comparative Peer Analysis
When compared to its pharmaceutical and biotechnology peers, NGL Fine Chem’s valuation remains on the higher side but is justified by its growth prospects and financial health. For instance, Bliss GVS Pharma trades at a P/E of 25.71 and EV/EBITDA of 19.58, while Kwality Pharma is classified as very expensive with a P/E of 34.06 and EV/EBITDA of 20.65. Other peers such as Venus Remedies and Lincoln Pharma present fair valuations with P/E ratios below 20 and EV/EBITDA ratios near 12.
Notably, NGL Fine Chem’s PEG ratio of 0.28 suggests undervaluation relative to its earnings growth, a positive signal for investors seeking growth at a reasonable price. This contrasts with higher PEG ratios among some peers, such as Jagsonpal Pharma at 2.25, indicating that despite its premium valuation, NGL Fine Chem offers attractive growth-adjusted value.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
Financial Performance and Quality Metrics
NGL Fine Chem’s return on capital employed (ROCE) is a healthy 13.29%, while return on equity (ROE) stands at 14.59%, both indicators of efficient capital utilisation and shareholder value creation. The company’s dividend yield remains modest at 0.06%, reflecting a focus on reinvestment for growth rather than income distribution.
Its enterprise value to capital employed ratio of 4.68 and EV to sales of 3.67 further highlight operational efficiency and market confidence in the company’s revenue-generating capabilities. These metrics, combined with a micro-cap market capitalisation and a Mojo Score of 71.0, underpin the recent upgrade from Hold to Buy on 22 May 2026 by MarketsMOJO, signalling improved sentiment and potential for further upside.
Price Momentum and Market Returns
The stock’s price momentum has been exceptional, with a one-week return of 27.51% and a one-month return of 28.24%, dwarfing the Sensex’s modest 1.56% and negative 0.23% returns respectively. Over the past year, NGL Fine Chem has surged 127.51%, while the Sensex declined by 6.40%. Even on a longer horizon, the stock’s 10-year return of 1,017.97% far exceeds the benchmark’s 195.54%, underscoring its strong growth trajectory and resilience.
Such outperformance is a key factor in the valuation re-rating, as investors increasingly recognise the company’s ability to deliver superior returns in a challenging market environment.
Thinking about NGL Fine Chem Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Valuation Outlook and Investor Considerations
While NGL Fine Chem’s valuation remains elevated compared to some peers, the shift from very expensive to expensive suggests a more balanced risk-reward profile. The company’s strong fundamentals, robust earnings growth, and superior market returns justify a premium, but investors should remain mindful of the micro-cap nature and attendant liquidity risks.
Its PEG ratio below 0.3 is particularly noteworthy, signalling that earnings growth is outpacing the price increase, a favourable sign for long-term investors. The recent upgrade to a Buy rating by MarketsMOJO reflects this improved valuation attractiveness and the company’s potential to sustain momentum.
Investors should also consider the broader pharmaceutical sector dynamics, where innovation, regulatory approvals, and global demand trends can materially impact valuations. NGL Fine Chem’s positioning within this sector, combined with its financial discipline, places it well for continued outperformance.
Conclusion
NGL Fine Chem Ltd’s recent valuation recalibration from very expensive to expensive, coupled with strong price momentum and solid financial metrics, marks a significant development for investors seeking growth opportunities in the pharmaceuticals and biotechnology sector. The company’s superior returns relative to the Sensex and peers, alongside a favourable PEG ratio and upgraded Mojo Grade to Buy, underscore its renewed price attractiveness.
While the premium valuation warrants cautious optimism, the comprehensive analysis of financial health, operational efficiency, and market performance supports a positive outlook. Investors looking for a micro-cap stock with strong growth credentials and improving valuation parameters may find NGL Fine Chem an appealing addition to their portfolio.
Only Rs. 20,999 - Get MojoOne + Stock of the Week for 3 Years Get 71% Off →
